NCT02043691 · University of Alabama at Birmingham
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
What this study is about
This is a single-center study to evaluate the safety and effectiveness of three experimental devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch pathologies involving the at least one brachiocephalic artery or visceral vessels.
View original scientific description
This is a single-center study to evaluate the safety and effectiveness of three investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch pathologies involving the at least one brachiocephalic artery or visceral vessels. The three investigational devices offer an endovascular approach to treat complex aortic pathologies that cannot be treated with commercially available devices. This customized, endovascular approach has the potential to decrease hospital length of stay, pulmonary complications, and in-hospital mortality.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Juxtarenal, suprarenal, and thoracoabdominal aortic pathology as follows in hemodynamically stable patients:
- Intact or contained ruptured aortic or aortoiliac aneurysms (atherosclerotic/degenerative or saccular) involving or in close approximation to the visceral segment of the aorta.
- Diameter \> 5.5 cm if asymptomatic, or 5.0 cm with enlargement of \> 0.5 cm in 6 months.
- History of growth \> 0.5 cm per year
- Any size if ruptured or symptomatic
- Penetrating aortic ulcer (PAU)
- \> 2.0 cm in depth
- Any size if contained ruptured or symptomatic
- Subacute (\>14 days) or chronic (\>20 days) aortic dissection with aneurysmal degeneration with at least one of the following:
- Total aortic diameter \> 5.5 cm if asymptomatic
- Total aortic diameter \> 4.5 cm if symptomatic
- Total aortic diameter \> 5.0 cm and history of growth \> 0.5 cm in 6 months
- Aortic Arch pathology:
- Aneurysm, Ascending thoracic aortic pseudoaneurysm, Type A thoracic aortic dissection, Retrograde type A thoracic aortic dissection between the Sinus of Valsalva and the innominate artery orifice (without involvement of the Aortic Valve), or Ascending penetrating aortic ulcer with and without intramural hematoma
- Suitable iliac artery and brachial artery access
- Absence of severe landing zone (\> 90 degree) angulation that would preclude necessary device delivery/seal/fixation.
- Suitable iliac artery access to accommodate device delivery system.
- Target arteries for arch branches:
- \< 24 mm diameter
- Adequate landing zone length to obtain proximal and distal seal.
- Free from dissection precluding adequate seal in distal landing zone of branch stent and severe tortuosity/thrombus/calcification.
- Aortic Arch Aneurysm
- Proximal aortic fixation zone:
- Native aorta or surgical graft
- Diameter: 20 - 42 mm
- Proximal neck length \> 20 mm
- Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion.
- Distal aortic fixation zone:
- Native aorta or surgical graft
- Diameter: 20 - 44 mm
- Distal neck length \> 20 mm. However, if dissection, distal graft may land in dissected aorta.
- Supra-aortic trunk (brachiocephalic) vessels (Any combination of arteries may be used for repair) A. Innominate artery
- Native vessel or surgical graft
- Diameter: 8 - 22 mm
- Length of sealing zone \> 10 mm
- Acceptable tortuosity B. Left (or right) common carotid artery <!-- -->
- Native vessel or surgical graft
- Diameter 5 - 20 mm
- Length of sealing zone \> 10 mm C. Left (or right) subclavian artery <!-- -->
- Native vessel or surgical graft
- Diameter 5 - 20 mm
- Length of sealing zone \> 10 mm
- Aortic Dissection
- Access into the true lumen from the groin and at least one supra-aortic trunk vessel.
- Seal zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen.
- Seal zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen or surgically created.
- True lumen size large enough to deploy the device and still gain access into the target branch. General
Exclusion criteria
- Less than 18 years of age
- Life expectancy less than 12 months based on the surgeon's assessment
- Pregnant or breastfeeding or planning on becoming pregnant within 60 months
- Inability or refusal to give informed consent
- Unwilling or unable to comply with the follow-up schedule
- Less than 30 days beyond primary endpoint for other investigative drug or device study Medical Exclusion Criteria:
- Known allergy to the device components (i.e. stainless steel, polyester, solder, gold, or nitinol)
- History of anaphylactic reaction to contrast material that cannot be adequately premedicated
- Systemic or local infection that may increase the risk of endovascular graft infection.
- Baseline eGFR \< 30 mL/min (calculated by the Modification of Diet in Renal Disease formula) and not on hemo- or peritoneal dialysis. If the patient is currently on dialysis, or is currently planning on initiating dialysis, then they may undergo repair.
- Body habitus that would inhibit X-ray visualization of the aorta.
- Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair.
- Unstable angina, defined as a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina.
- Irreversible coagulopathy Anatomical Exclusion Criteria:
- Aortic transection due to acute trauma.
- Infectious ("mycotic") etiology of the aortic disease.
- Significant occlusive disease or tortuosity precluding delivery of the device components.
- Juxtarenal, Suprarenal, and Thoracoabdominal:
- Proximal Landing zone \< 20 mm in length. The proximal landing zone can be within zones 2 through 8, with least 20 mm of proximal seal and fixation in aorta or Dacron.
- Proximal neck, defined as the thoracic aorta distal to the native left carotid artery, measured outer wall to outer wall on a sectional image (CT) \> 41 mm in diameter or \< 18 mm in diameter
- Distal landing zone \< 20 mm in length if the landing zone is in the aorta, or \< 20 mm if the landing zone is in the iliac arteries or in Dacron (in the event the patient has had a previous or concomitant aortic or aorto-iliac reconstruction).
- Untreatable branch vessel stenosis.
- Anatomy that would not allow maintenance of at least one patent hypogastric artery.
- Signs that the inferior mesenteric artery (IMA) is indispensable (i.e. angiographic visualization or a large IMA, filling of superior mesenteric artery (SMA) via collaterals, stenosis of celiac or SMA or oblique views) and the indispensable IMA is not amenable to treatment with a graft branch or fenestration.
- Branching, duplication, aneurysm or untreatable stenosis of the celiac, SMA or renal arteries that would preclude implantation of the investigational devices.
- Aortic arch:
- Proximal neck \> 44 mm or \< 28 mm in diameter
- Inadequate landing zone to allow adequate distal seal of exclusion of false lumen perfusion in dissection.
- Untreatable branch vessel stenosis.
- Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access.
- Patients qualifying for an industry-sponsored study allowing for a similar repair will be enrolled in the industry-sponsored study.
Where
- Birmingham, Alabama
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jan 6, 2026 · Source of record for eligibility and locations